KR20210129051A - 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제 - Google Patents

단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제 Download PDF

Info

Publication number
KR20210129051A
KR20210129051A KR1020217025767A KR20217025767A KR20210129051A KR 20210129051 A KR20210129051 A KR 20210129051A KR 1020217025767 A KR1020217025767 A KR 1020217025767A KR 20217025767 A KR20217025767 A KR 20217025767A KR 20210129051 A KR20210129051 A KR 20210129051A
Authority
KR
South Korea
Prior art keywords
degrees
theta
crystalline form
ray powder
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217025767A
Other languages
English (en)
Korean (ko)
Inventor
훙 린
췬 리
마크 안드레스
화핑 장
Original Assignee
프렐루드 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프렐루드 테라퓨틱스, 인코포레이티드 filed Critical 프렐루드 테라퓨틱스, 인코포레이티드
Publication of KR20210129051A publication Critical patent/KR20210129051A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
KR1020217025767A 2019-02-13 2020-02-13 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제 Withdrawn KR20210129051A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962805175P 2019-02-13 2019-02-13
US62/805,175 2019-02-13
US201962805726P 2019-02-14 2019-02-14
US62/805,726 2019-02-14
PCT/US2020/018185 WO2020168125A1 (en) 2019-02-13 2020-02-13 Selective inhibitor of protein arginine methyltransferase 5 (prmt5)

Publications (1)

Publication Number Publication Date
KR20210129051A true KR20210129051A (ko) 2021-10-27

Family

ID=69845552

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217025767A Withdrawn KR20210129051A (ko) 2019-02-13 2020-02-13 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제

Country Status (12)

Country Link
US (1) US20220160713A1 (https=)
EP (1) EP3924360A1 (https=)
JP (1) JP2022521491A (https=)
KR (1) KR20210129051A (https=)
CN (1) CN113811539A (https=)
AU (1) AU2020223058A1 (https=)
BR (1) BR112021015796A2 (https=)
CA (1) CA3129612A1 (https=)
IL (1) IL285536A (https=)
MX (1) MX2021009796A (https=)
WO (1) WO2020168125A1 (https=)
ZA (1) ZA202105887B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
WO2022026892A1 (en) 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
US20220251088A1 (en) * 2020-12-10 2022-08-11 Prelude Therapeutics, Incorporated Processes for Making PRMT5 Inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US20170198006A1 (en) * 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016044576A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor
MX2017010844A (es) * 2015-02-24 2017-12-07 Pfizer Derivados de nucleosidos sustituidos utiles como agentes anticancerosos.
MA41828A (fr) * 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI870767B (zh) * 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
EP3939986A1 (en) * 2017-08-09 2022-01-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US12552826B2 (en) * 2018-08-07 2026-02-17 Merck Sharp & Dohme Llc PRMT5 inhibitors

Also Published As

Publication number Publication date
WO2020168125A1 (en) 2020-08-20
AU2020223058A1 (en) 2021-09-09
BR112021015796A2 (pt) 2021-10-13
CA3129612A1 (en) 2020-08-20
CN113811539A (zh) 2021-12-17
MX2021009796A (es) 2021-09-08
IL285536A (en) 2021-09-30
ZA202105887B (en) 2024-12-18
JP2022521491A (ja) 2022-04-08
US20220160713A1 (en) 2022-05-26
EP3924360A1 (en) 2021-12-22

Similar Documents

Publication Publication Date Title
US11078205B2 (en) Selective inhibitors of protein arginine methlytransferase 5 (PRMT5)
US20230174539A1 (en) Substituted Pyrrolo[2,3-D]Pyrimidines As Inhibitors Of Protein Arginine Methyl Transferase 5 (PRMT5)
KR20210129051A (ko) 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제
US20250367205A1 (en) Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
KR20240166545A (ko) 다형성 화합물 및 이의 용도
US20230357275A1 (en) Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
EA043295B1 (ru) Селективный ингибитор протеин-аргинин-метилтрансферазы 5 (prmt5)
HK40067540A (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA044352B1 (ru) Селективные ингибиторы протеинаргининметил трансферазы 5 (prmt5)
HK40031042B (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
HK40031042A (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301